AU2021316675A1 - Methods of treatment of trigeminal neuralgia - Google Patents

Methods of treatment of trigeminal neuralgia Download PDF

Info

Publication number
AU2021316675A1
AU2021316675A1 AU2021316675A AU2021316675A AU2021316675A1 AU 2021316675 A1 AU2021316675 A1 AU 2021316675A1 AU 2021316675 A AU2021316675 A AU 2021316675A AU 2021316675 A AU2021316675 A AU 2021316675A AU 2021316675 A1 AU2021316675 A1 AU 2021316675A1
Authority
AU
Australia
Prior art keywords
compound
formula
pharmaceutically acceptable
composition
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021316675A
Other languages
English (en)
Inventor
George GARIBALDI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Noema Pharma AG
Original Assignee
Noema Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noema Pharma AG filed Critical Noema Pharma AG
Publication of AU2021316675A1 publication Critical patent/AU2021316675A1/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
AU2021316675A 2020-07-30 2021-07-30 Methods of treatment of trigeminal neuralgia Pending AU2021316675A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063058630P 2020-07-30 2020-07-30
US63/058,630 2020-07-30
PCT/EP2021/071376 WO2022023519A1 (en) 2020-07-30 2021-07-30 Methods of treatment of trigeminal neuralgia

Publications (1)

Publication Number Publication Date
AU2021316675A1 true AU2021316675A1 (en) 2023-01-19

Family

ID=77520687

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021316675A Pending AU2021316675A1 (en) 2020-07-30 2021-07-30 Methods of treatment of trigeminal neuralgia

Country Status (15)

Country Link
US (2) US20230172922A1 (https=)
EP (1) EP4188370A1 (https=)
JP (1) JP2023540849A (https=)
KR (1) KR20230047132A (https=)
CN (1) CN115989024A (https=)
AR (1) AR123108A1 (https=)
AU (1) AU2021316675A1 (https=)
BR (1) BR112023001621A2 (https=)
CA (1) CA3182457A1 (https=)
CL (1) CL2023000261A1 (https=)
IL (1) IL300124A (https=)
MX (1) MX2023001288A (https=)
PH (1) PH12023550204A1 (https=)
TW (1) TW202220649A (https=)
WO (1) WO2022023519A1 (https=)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100548299C (zh) * 2001-01-05 2009-10-14 伊莱利利公司 兴奋性氨基酸受体拮抗剂
UA80888C2 (en) 2003-06-05 2007-11-12 Hoffmann La Roche Imidazole derivatives as glutmate receptor antagonists
NZ551253A (en) * 2004-06-01 2010-07-30 Hoffmann La Roche Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as MGLU5 receptor antagonists
MY148217A (en) * 2006-12-21 2013-03-29 Hoffmann La Roche Polymorphs of a mglur5 receptor antagonist
US8211882B2 (en) * 2008-03-08 2012-07-03 Richard Delarey Wood Glutamate receptor modulators and therapeutic agents
WO2011035209A1 (en) * 2009-09-17 2011-03-24 Vanderbilt Universtiy Substituted benzamide analogs as mglur5 negative allosteric modulators and methods of making and using the same

Also Published As

Publication number Publication date
TW202220649A (zh) 2022-06-01
EP4188370A1 (en) 2023-06-07
CN115989024A (zh) 2023-04-18
CL2023000261A1 (es) 2023-09-08
AR123108A1 (es) 2022-10-26
US20230172922A1 (en) 2023-06-08
WO2022023519A1 (en) 2022-02-03
MX2023001288A (es) 2023-04-28
CA3182457A1 (en) 2022-02-03
IL300124A (en) 2023-03-01
PH12023550204A1 (en) 2024-06-24
US20250345320A1 (en) 2025-11-13
BR112023001621A2 (pt) 2023-04-04
KR20230047132A (ko) 2023-04-06
JP2023540849A (ja) 2023-09-27

Similar Documents

Publication Publication Date Title
US20250099445A1 (en) Methods of treatment of tuberous sclerosis complex
EA029180B1 (ru) Лекарственная форма лакозамида для приема один раз в сутки
AU2009282818A1 (en) Methods for treating neuropathic pain
IL298713A (en) Use of a phosphodiesterase 10 inhibitor to treat Tourette syndrome
US20250345320A1 (en) Methods of treatment of trigeminal neuralgia
OA21124A (en) Methods of treatment of trigeminal neuralgia.
EP3592350B1 (en) Pharmaceutical compositions comprising metyrapone and oxazepam and uses thereof
WO2024118936A1 (en) 2-arylbenzimidazole compounds for the treatment of hemoglobinopathies
OA21484A (en) Methods of treatment of tuberous sclerosis complex.
WO2025195451A1 (en) Pharmaceutical compositions, dosage forms, and methods of preparation and use thereof
EP1485352B1 (de) Aza-spiroverbindungen zur behandlug von schmerzen
WO2025096684A1 (en) Err modulators
EA042299B1 (ru) Фармацевтические композиции и их применения